0 Comment(s)
Print
E-mail China.org.cn, October 25, 2024
The Center for Information of the National Medical Products Administration (NMPA) officially opened on Oct. 23 in the BioPark of Beijing Economic and Technological Development Area, also known as Beijing E-Town. This marks the establishment of all six core NMPA centers in Beijing E-Town.
The fix centers, including the Center for Drug Evaluation, Center for Food and Drug Inspection and Verification, Center for Drug Reevaluation Center (National Center for ADR Monitoring), and Center for Medical Device Evaluation, provide administrative approval and enterprise qualification certification, supporting the high-quality development of biotechnology and health industries.
A Beijing E-Town official explained the significance of these centers. The Center for Drug Evaluation organizes technical reviews for drug registration, while the Center for Medical Device Evaluation handles applications for domestic third-class and imported medical devices. From the perspective of industry rules, review is a key node for industry entry. Integrating the regulatory resources of the NMPA can increase the service guidance for the registration and listing of innovative drugs and devices.
The six centers are located in BioPark's headquarters cluster area. BioPark is designed to provide a comprehensive ecosystem for biomedical companies, offering spaces for headquarters, R&D, medical and engineering integration, and pharmaceutical intelligent manufacturing.
"We will systematically promote innovation in science, technology, applications and mechanisms," a BioPark spokesperson said. "We'll integrate policy measures from various departments in supervision, intellectual property protection and medical and human genetic resource management to form an industrial policy system aligned with international rules."
